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Abstract
Background: The risk of psoriasis in patients with breast cancer is largely unknown, as available evidence is limited
to case findings. We systematically examined the incidence and risk factors of psoriasis in patients with breast
cancer.
Methods: A Swedish nationwide cohort of 56,235 breast cancer patients (2001–2012) was compared to 280,854
matched reference individuals from the general population to estimate the incidence and hazard ratio (HR) of new-
onset psoriasis. We also calculated HRs for psoriasis according to treatment, genetic, and lifestyle factors in a
regional cohort of 8987 patients.
Results: In the nationwide cohort, 599 patients with breast cancer were diagnosed with psoriasis during a median
follow-up of 5.1 years compared to 2795 cases in the matched reference individuals. This corresponded to an
incidence rate of 1.9/1000 person-years in breast cancer patients vs. 1.7/1000 person-years in matched reference
individuals. Breast cancer patients were at an increased risk of psoriasis (HR = 1.17; 95% confidence interval (CI) =
1.07–1.28), especially its most common subtype (psoriasis vulgaris; HR = 1.33; 95% CI = 1.17–1.52). The risk of
psoriasis vulgaris was highest shortly after diagnosis but remained increased up to 12 years. Treatment-specific
analyses indicated a higher risk of psoriasis in patients treated with radiotherapy (HR = 2.44; 95% CI = 1.44–4.
12) and mastectomy (HR = 1.54, 95% CI = 1.03–2.31). Apart from treatment-specific effects, we identified
genetic predisposition, obesity, and smoking as independent risk factors for psoriasis in breast cancer patients.
Conclusions: The incidence of psoriasis is slightly elevated among patients with breast cancer, with
treatment, lifestyle, and genetic factors defining the individual risk profile.
Background
Psoriasis is a complex autoimmune skin disorder charac-
terized by patches of abnormal skin. The prevalence of
the condition has been estimated to be between 2% to
3% in the general population of Western countries [1, 2].
Common symptoms include red, inflamed skin and scaly
plaques. More severe complications, such as inflamma-
tory arthritis, can result in joint deformations and dis-
ability. Patients suffering from psoriasis typically report a
poor health-related quality of life and endure significant
social stigma [3–5].
Clinical observations suggest a potential increased risk
of psoriasis in patients with breast cancer, which has
mainly been attributed to skin trauma due to surgery [6]
or radiotherapy-induced skin reactions [7]. Estimates of
the incidence and relative risk of psoriasis as compared
to the general population, however, are unknown, as the
available evidence is limited to case reports with a pre-
dominant focus on patients who were previously diag-
nosed with psoriasis [8–11]. Moreover, no study to date
has systematically examined the impact of different
treatment-related factors including surgery and radio-
therapy on psoriasis incidence, despite the fact that skin
trauma has been shown to be a triggering factor for
more than half of the new-onset psoriasis cases [12].
Considering the rising incidence of breast cancer and
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the large proportion of patients undergoing radiotherapy
and surgery, it is of importance to better understand the
risk of psoriasis in women treated with such modalities.
Psoriasis is an autoimmune disease with genetic vari-
ants and lifestyle factors (including alcohol consumption,
smoking, and obesity) influencing disease susceptibility
[13–16]. Since cancer cells and immunosuppressive can-
cer treatments including chemotherapy can influence
the immune system of patients with breast cancer, the
contribution of genetic and lifestyle factors to psoriasis
risk may be different in this patient population [17].
Whether risk factors identified in the general population
predispose to psoriasis in these patients, however, has
not been assessed previously.
We aimed to assess the relative risk and incidence
rates of psoriasis in patients with breast cancer as com-
pared to the general population, overall and by time
since diagnosis. We specifically evaluated risks by radio-
therapy and surgery as sources of skin trauma-triggering
events. We also studied the impact of previously identi-
fied psoriasis risk factors (i.e., genetic predisposition and
lifestyle factors) to comprehensively understand the fac-
tors influencing disease susceptibility in this patient
population.
Methods
Study populations
We analyzed two population-based cohorts: a Swedish
nationwide cohort of breast cancer patients and a re-
gional breast cancer cohort (Table 1, Additional file 1:
Figure S1).
The nationwide cohort of breast cancer patients com-
prised women who were part of the 1990 national cen-
sus of Sweden and were diagnosed with primary invasive
breast cancer between 2001 and 2011, at age 20–80
years (n = 56,976). Information on breast cancer diagno-
ses was obtained through the Swedish Cancer Register,
which was founded in 1958 and is managed by the Na-
tional Board of Health and Welfare. Since the focus of
our study is on the risk of new-onset psoriasis, patients
who had been diagnosed with psoriasis before the date
of the breast cancer diagnosis were excluded, leaving
56,235 patients in the cohort (Table 1). To compare the
risk of psoriasis, we randomly sampled up to 5 women
from the general female population matched on age,
county of residence, and social economic status
(obtained from the 1990 national census of Sweden, cat-
egorized as blue collar workers, white collar workers,
self-employed workers, farmers, and others). Each refer-
ence individual was alive and free of cancer and psoriasis
on the date of the matched patient’s diagnosis (the index
date). In total, 321 women could not be matched to an
index case, resulting in 280,854 matched reference indi-
viduals. Follow-up of the cohorts started from the index
date (i.e., diagnosis date for breast cancer patients) and
ended on 31 December 2012, date of death, date of emi-
gration, date of a secondary cancer diagnosis, or date of
psoriasis diagnosis, whichever came first. Information on
death and emigration was obtained through cross-
linking the cohorts to the Swedish Causes of Death
Register and the Swedish Migration Register, using the
unique personal identity number.
LIBRO-1 is a regional breast cancer cohort including
women diagnosed with primary invasive breast cancer
(at age 20–80 years) between 2001 and 2008 in the
Stockholm-Gotland area (n = 8987). Detailed informa-
tion on tumor characteristics and treatment at baseline
was available in LIBRO-1 through linkage to the Swedish
breast cancer quality registers (Information Networks
for Cancer Treatment and Regional Cancer Center
Stockholm-Gotland), including tumor size, estrogen re-
ceptor status, metastasis status, as well as information
on intended treatment in terms of surgery, radiotherapy,
chemotherapy, and endocrine therapy. The LIBRO-1
Table 1 Descriptive characteristics of the nationwide and regional breast cancer cohorts
Nationwide cohort n = 56,235 Regional cohort n =8987
Cohort period 2001–2012 2001–2013
Age at diagnosis (years)
Mean (SD) 60.1 (11.0) 58.6 (11.2)
Minimum–maximum 20–80 23–80
Duration of follow-up (years)
Median (IQR) 5.1 (5.4) 7.7 (4.3)
Total no. of person-years at risk 307,684 68,243
Cases of psoriasis 599 150
Age at psoriasis diagnosis (SD) 62.5 (10.0) 63.6 (10.2)
SD standard deviation, IQR interquartile range
The nationwide cohort includes women diagnosed with primary invasive breast cancer at age 20–80 years between 2001 and 2011. In this cohort, follow-up is
complete until 31 December 2012. The regional cohort includes women diagnosed with primary invasive breast cancer at age 20–80 years between 2001 and
2008; all patients in this cohort have complete follow-up until 31 December 2013
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cohort was linked to the Swedish Causes of Death Regis-
ter and the Swedish Migration Register to obtain infor-
mation on date of death and emigration. Person-time
was defined in the same way as for the nationwide co-
hort, except for an extension of the follow-up until 31
December 2013.
Psoriasis diagnoses
All psoriasis cases were identified through the Swedish
Patient Register [18], which was established in 1964 and
achieved nationwide coverage for inpatient hospitaliza-
tions in Sweden since 1987. From 2001, hospital-based
outpatient physician visits have also been reported by
Swedish counties. Diagnoses were coded according to
the 7th–10th Swedish Revision of the International Clas-
sification of Diseases (ICD) codes (ICD-7 (1964–1968):
706; ICD-8 and ICD-9 (1969–1996): 696; ICD-10 (1997–
present): L40). The validity of a psoriasis diagnosis in the
inpatient and outpatient registers is 81% [19]. The first
psoriasis subtype recorded was defined by the use of the
ICD-10 code into: psoriasis vulgaris (L40.0), palmoplan-
tar pustulosis (L40.3), and arthropathic psoriasis (L40.5).
To ensure specificity, only primary discharge diagnoses
were considered for the present analysis.
Genetic and lifestyle risk factors
A subset of 4365 breast cancer patients within LIBRO-1
who were alive in 2009 consented to participate in a
questionnaire-based study and gave a blood sample for
genetic analyses. Patients’ lifestyle information on
cigarette smoking, body mass index (BMI), alcohol con-
sumption, and physical activity prior to diagnosis was re-
trieved from the self-reported questionnaire. Genotyping
was carried out using a custom Illumina iSelect array
(iCOGS) comprising 211,155 single nucleotide polymor-
phisms (SNPs) [20]. Details of the iCOGS array design,
sample handling, and quality control processes have
been described elsewhere [20]. To assess genetic predis-
position to psoriasis, we selected 35 genome-wide sig-
nificant SNPs reported by a recent meta-analysis of
psoriasis genome-wide association studies (GWASs) [21]
for constructing a polygenic risk score (PRS) using a
scoring routine in the PLINK software v1.9 [22]. All
SNPs were not directly genotyped on iCOGS, but im-
puted instead using the 1000 Genomes Project March
2012 release as a reference [23]. All SNPs passed quality
control (minor allele frequency (MAF) ≥ 0.01 and R2/IM-
PUTE info-score ≥ 0.5), and for each individual breast
cancer patient, a weighted PRS was calculated using the
following formula:
PRS ¼ β1x1 þ β2x2 þ ::::βkxk þ βnxn
where β is the per-allele log odds ratio (OR) for psoriasis
associated with the risk allele for SNP k, xk is the num-
ber of alleles for the same SNP (0, 1, 2), and n is the
total number of disease SNPs included in the profile.
The SNPs and corresponding ORs (weights) used for the
derivation of the PRS are summarized in Additional file 1:
Table S1. For analysis, patients were categorized by tertiles
of the PRS.
Statistical analysis
To assess the risk of psoriasis in patients with breast
cancer, we used stratified Cox regression models (i.e.,
Cox regression models conditioned on the matching var-
iables age, county of residence, and social economic sta-
tus) and calculated hazard ratios (HRs) for psoriasis in
patients with breast cancer, overall, and by dividing the
follow-up time into periods of 0 to < 0.5 year, 0.5 to <
1 year, 1–5 years, and >5 years, and by age at diagnosis
(20–44 years, 45–54 years, 55–64 years, and 65–80
years). The underlying time scale for all the analyses was
time since diagnosis. The stratified Cox model has been
a recommended analysis approach for matched cohort
data, and it deals with the presence of potential con-
founders (measured and unmeasured) as well as any im-
balances in the matching scheme caused by censoring
[24–26]. Potential effect modification of age was tested
by adding an interaction term of breast cancer (yes vs.
no) with age (20–44 years, 45–54 years, 55–64 years,
and 65–80 years) to the Cox model. We used Kaplan-
Meier analyses to assess the cumulative incidence of
psoriasis in breast cancer patients and matched refer-
ence individuals. This analysis approach does not ac-
count for the competing risk of death. Therefore, to
address this potential bias, we also analyzed the data
using competing risk models, treating mortality as a
competing event.
To identify the risk factors for psoriasis in patients
with breast cancer, we analyzed associations with cancer
treatment in the regional cohort of breast cancer pa-
tients. The basic model (Model 1) was adjusted for age
at breast cancer diagnosis and calendar period. In the
multivariable model (Model 2), all treatment variables
were entered for mutual adjustment as fixed covariates.
To investigate potential confounding by disease severity,
a sensitivity analysis was conducted in which tumor
characteristics were added to Model 2. We further stud-
ied the effect of genetic predisposition and lifestyle fac-
tors in the subcohort with questionnaire and genotyping
data. These analyses were conducted in the same man-
ner as the analysis of cancer treatments, with a basic
model (Model 1) adjusting for age at breast cancer diag-
nosis and calendar period, and a multivariable model
(Model 2) including all risk factors, including identified
treatment-related risk factors. Ordinary Cox regression
was used for all risk factor analyses, and the proportional
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hazards assumption was tested using Schoenfeld
residuals.
Statistical analyses were performed using SAS (version
9.4; SAS Institute Inc., Cary, NC, USA) and Stata soft-
ware (version 14.0; Stata Corporation, College Station,
TX, USA). The study was approved by the Regional
Ethical Review Board in Stockholm.
Results
Risk of psoriasis in patients with breast cancer as
compared to matched reference individuals
In total, 599 cases of psoriasis were observed during a
median follow-up of 5.1 years in the nationwide breast
cancer cohort compared to 2795 cases in the matched
reference individuals. This corresponded to an incidence
rate of 1.9/1000 person-years in breast cancer patients
vs. 1.7/1000 person-years in the matched reference indi-
viduals, indicating a 0.2/1000 person-years of absolute
risk increase (95% confidence interval (CI) = 0.1/1000–
0.4/1000). The most common psoriasis subtype was
psoriasis vulgaris (298 out of 599), followed by palmo-
plantar pustulosis and arthropathic psoriasis. The 5-year
cumulative incidence of psoriasis in breast cancer pa-
tients and in the matched reference individuals was 1.0%
and 0.8%, respectively (Fig. 1). These estimates were very
similar to those observed in competing risk analyses,
indicating that bias due to the competing risk of death is
negligible.
Patients with breast cancer experienced a 17% in-
creased risk of being diagnosed with psoriasis during
follow-up (HR = 1.17; 95% CI = 1.07–1.28) (Table 2). The
increased risk of psoriasis was mainly attributed to psor-
iasis vulgaris (HR = 1.33, 95% CI = 1.17–1.52), with no
overall risk increase being observed for the other psoria-
sis subtypes. Analyses by time since diagnosis showed
that the risk of psoriasis was highest in the second half
of the first year after diagnosis (HR = 1.68, 95% CI =
1.30–2.19). The risk of psoriasis vulgaris was long-term
increased, with the HR remaining significant between 5
and 12 years after diagnosis (HR = 1.33, 95% CI = 1.06–
1.68). Risk of psoriasis did not vary among different age
groups, and the interaction between a breast cancer
diagnosis and age was not significant (P for interaction
= 0.84).
Risk of psoriasis by treatment, genetic predisposition, and
lifestyle factors in patients with breast cancer
Analyses by treatment characteristics showed no effect
of chemotherapy and endocrine therapy on psoriasis risk
(Table 3). Radiotherapy, in contrast, was associated with
a twofold increased risk after adjusting for surgery,
chemotherapy, and endocrine therapy (HR = 2.44; 95%
Fig. 1 Cumulative incidence of psoriasis in the nationwide cohort of breast cancer patients and matched individuals. Kaplan-Meier estimates of
the cumulative risk of psoriasis by time since diagnosis, in breast cancer patients and matched individuals from the general population
Yang et al. BMC Medicine  (2017) 15:154 Page 4 of 8
Ta
b
le
2
H
az
ar
d
ra
tio
s
fo
r
ps
or
ia
si
s
in
th
e
na
tio
nw
id
e
br
ea
st
ca
nc
er
co
ho
rt
N
o.
of
PY
s
A
ny
ps
or
ia
si
s
Ps
or
ia
si
s
vu
lg
ar
is
Pa
lm
op
la
nt
ar
pu
st
ul
os
is
A
rt
hr
op
at
hi
c
ps
or
ia
si
s
To
ta
l/c
as
e
no
.
H
R
(9
5%
C
I)
C
as
e
no
.
H
R
(9
5%
C
I)
C
as
e
no
.
H
R
(9
5%
C
I)
C
as
e
no
.
H
R
(9
5%
C
I)
O
ve
ra
ll
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
1,
66
6,
03
8
28
0,
85
4/
27
95
1.
00
(R
ef
.)
12
34
1.
00
(R
ef
.)
48
8
1.
00
(R
ef
.)
43
3
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
30
7,
68
4.
8
56
,2
35
/5
99
1.
17
(1
.0
7–
1.
28
)
29
8
1.
33
(1
.1
7–
1.
52
)
95
1.
04
(0
.8
4–
1.
30
)
75
0.
94
(0
.7
3–
1.
20
)
Ti
m
e
si
nc
e
di
ag
no
si
s
0
to
<
0.
5
ye
ar
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
13
9,
88
6.
5
28
0,
85
4/
23
8
1.
00
(R
ef
.)
86
1.
00
(R
ef
.)
48
1.
00
(R
ef
.)
51
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
27
,7
80
.3
5
56
,2
35
/5
0
1.
08
(0
.8
0–
1.
47
)
23
1.
35
(0
.8
5–
2.
14
)
13
1.
40
(0
.7
6–
2.
59
)
4
0.
41
(0
.1
5–
1.
13
)
0.
5
to
<
1
ye
ar
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
13
8,
58
7.
1
27
8,
47
3/
22
8
1.
00
(R
ef
.)
11
3
1.
00
(R
ef
.)
27
1.
00
(R
ef
.)
32
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
27
,3
01
.1
55
,0
33
/7
5
1.
68
(1
.3
0–
2.
19
)
37
1.
66
(1
.1
5–
2.
41
)
15
2.
88
(1
.5
2–
5.
43
)
5
0.
80
(0
.3
1–
2.
07
)
1–
5
ye
ar
s
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
86
1,
20
2.
7
27
5,
87
0/
14
51
1.
00
(R
ef
.)
62
9
1.
00
(R
ef
.)
28
1
1.
00
(R
ef
.)
21
9
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
16
2,
01
1.
6
54
,1
56
/2
96
1.
09
(0
.9
6–
1.
24
)
14
6
1.
27
(1
.0
6–
1.
52
)
43
0.
81
(0
.5
8–
1.
12
)
44
1.
07
(0
.7
7–
1.
48
)
>
5
ye
ar
s
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
52
6,
36
2
15
9,
14
7/
87
8
1.
00
(R
ef
.)
40
6
1.
00
(R
ef
.)
13
2
1.
00
(R
ef
.)
13
1
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
90
,5
91
.8
1
28
,4
30
/1
78
1.
17
(0
.9
9–
1.
38
)
92
1.
33
(1
.0
6–
1.
68
)
24
1.
02
(0
.6
6–
1.
60
)
22
0.
98
(0
.6
2–
1.
56
)
A
ge
at
br
ea
st
ca
nc
er
di
ag
no
si
s
20
–4
4
ye
ar
s
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
15
8,
52
7.
2
25
,3
61
/1
85
1.
00
(R
ef
.)
75
1.
00
(R
ef
.)
30
1.
00
(R
ef
.)
46
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
28
,9
08
.3
6
50
99
/4
3
1.
35
(0
.9
7–
1.
90
)
24
1.
88
(1
.1
7–
3.
00
)
6
1.
08
(0
.4
5–
2.
62
)
6
0.
82
(0
.3
5–
1.
94
)
45
–5
4
ye
ar
s
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
38
9,
18
7.
5
61
,4
04
/7
07
1.
00
(R
ef
.)
28
5
1.
00
(R
ef
.)
15
5
1.
00
(R
ef
.)
12
2
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
72
,7
53
.4
8
12
,2
89
/1
51
1.
16
(0
.9
7–
1.
38
)
72
1.
39
(1
.0
7–
1.
81
)
28
0.
95
(0
.6
3–
1.
43
)
22
0.
97
(0
.6
1–
1.
53
)
55
–6
4
ye
ar
s
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
54
9,
42
5.
4
89
,3
47
/1
06
7
1.
00
(R
ef
.)
44
7
1.
00
(R
ef
.)
21
3
1.
00
(R
ef
.)
17
2
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
10
2,
75
3.
2
17
,8
50
/2
29
1.
14
(0
.9
9–
1.
32
)
10
9
1.
27
(1
.0
3–
1.
58
)
42
1.
04
(0
.7
4–
1.
45
)
23
0.
74
(0
.4
7–
1.
15
)
65
–8
0
ye
ar
s
M
at
ch
ed
re
fe
re
nc
e
co
ho
rt
56
8,
89
8.
3
10
4,
74
2/
83
6
1.
00
(R
ef
.)
42
7
1.
00
(R
ef
.)
90
1.
00
(R
ef
.)
93
1.
00
(R
ef
.)
Br
ea
st
ca
nc
er
co
ho
rt
10
3,
26
9.
8
20
,9
97
/1
76
1.
16
(0
.9
9–
1.
38
)
93
1.
27
(1
.0
1–
1.
59
)
19
1.
21
(0
.7
3–
2.
01
)
24
1.
30
(0
.8
2–
2.
07
)
CI
co
nf
id
en
ce
in
te
rv
al
,n
o.
nu
m
be
r,
PY
s
pe
rs
on
-y
ea
rs
,H
R
ha
za
rd
ra
tio
H
az
ar
d
ra
tio
of
ps
or
ia
si
s
in
th
e
na
tio
nw
id
e
br
ea
st
ca
nc
er
co
ho
rt
co
m
pa
re
d
to
ag
e,
re
si
de
nc
e
pl
ac
e,
an
d
so
ci
al
ec
on
om
ic
st
at
us
m
at
ch
ed
Sw
ed
is
h
fe
m
al
e
po
pu
la
tio
n
(a
ge
20
–8
0)
.S
ig
ni
fic
an
t
as
so
ci
at
io
ns
ar
e
de
no
te
d
in
bo
ld
fa
ce
.P
va
lu
es
fo
r
th
e
te
st
of
in
te
ra
ct
io
n
te
rm
of
br
ea
st
ca
nc
er
di
ag
no
si
s
an
d
ag
e
gr
ou
ps
ar
e
0.
84
,0
.4
9,
0.
91
,a
nd
0.
37
,r
es
pe
ct
iv
el
y,
fo
r
ps
or
ia
si
s
ov
er
al
l,
ps
or
ia
si
s
vu
lg
ar
is
,p
al
m
op
la
nt
ar
pu
st
ul
os
is
,a
nd
ar
th
ro
pa
th
ic
ps
or
ia
si
s
Yang et al. BMC Medicine  (2017) 15:154 Page 5 of 8
CI = 1.44–4.12). An increased risk of psoriasis was also
observed in breast cancer patients who underwent mast-
ectomy, compared to those who had a lumpectomy (HR
= 1.54, 95% CI = 1.03–2.31) in the multivariable adjusted
model (Model 2). A sensitivity analysis with additional
adjustment for tumor characteristics yielded similar re-
sults (Additional file 1: Table S2).
Table 4 shows the association of genetic and lifestyle fac-
tors with psoriasis risk in patients with breast cancer. A
significantly increased risk of psoriasis was found among
patients in the highest tertile of the psoriasis PRS com-
pared to those having lower genetic scores (HR = 2.94;
95% CI = 1.57–5.49, P for trend < 0.001). In the multivari-
able model (Model 2), regular cigarette smoking for more
than 1 year prior to diagnosis (HR = 1.59; 95% CI = 1.00–
2.52) and a BMI larger than 30 kg/m2 at diagnosis (HR =
2.10; 95% CI = 1.20–3.68) significantly increased the risk
of psoriasis in breast cancer patients. In the multivariable
model, a high level of physical activity (more than 2 h per
week) prior to diagnosis was shown to protect breast can-
cer patients from psoriasis; however, this effect was not
significant (HR = 0.59; 95% CI = 0.33–1.03).
Discussion
Key results
The incidence of psoriasis was 17% higher in breast can-
cer patients compared to the matched reference individ-
uals in this study. The relative risk of psoriasis was seen
within the first year after diagnosis and was mainly at-
tributed to an increased risk of psoriasis vulgaris (33%
higher). Treatment-specific analyses indicated an in-
creased risk of psoriasis in patients treated with radio-
therapy and mastectomy. Apart from treatment-specific
effects, we identified genetic predisposition, obesity, and
smoking as independent risk factors for psoriasis in pa-
tients with breast cancer.
Interpretation
Previous studies have reported a higher risk of skin dis-
orders such as dermatitis and skin infection in patients
with breast cancer [27, 28]. We found a slightly in-
creased risk of psoriasis in breast cancer patients as
compared to the general population. However, the over-
all incidence of psoriasis is low, and the absolute risk dif-
ferences observed were also rather small. Of note, the
cumulative incidence estimates of the current study are
based on primary clinical diagnoses of psoriasis from the
patient register (1%) and are lower than the estimate
Table 3 Hazard ratios for psoriasis in the regional breast cancer
cohort according to treatment characteristics
Total
no.
No.
of
cases
HR (95% CI)
Model 1 Model 2
Endocrine therapy
No 1533 27 1.00 (Ref.) 1.00 (Ref.)
Yes 7100 121 0.90 (0.59–1.36) 0.80 (0.52–1.24)
Chemotherapy
No 5544 102 1.00 (Ref.) 1.00 (Ref.)
Yes 3070 46 0.82 (0.57–1.19) 0.70 (0.47–1.04)
Radiotherapy
No 2061 23 1.00 (Ref.) 1.00 (Ref.)
Yes 6574 125 1.78 (1.14–2.78) 2.44 (1.44–4.12)
Surgery
Lumpectomy 5203 94 1.00 (Ref.) 1.00 (Ref.)
Mastectomy 3459 55 0.96 (0.69–1.34) 1.54 (1.03–2.31)
CI confidence interval, Total no. number of breast cancer patients, No. of cases
number of psoriasis cases, HR hazard ratio
Model 1: adjusted for age and calendar period of breast cancer diagnosis.
Model 2: Model 1 plus all the treatment factors. Significant associations are
denoted in boldface. Missingness on all variables is <5%. No evidence of non-
proportional hazards was found
Table 4 Hazard ratios for psoriasis in the regional breast cancer
cohort according to genetic and lifestyle factors
Total
no.
No.
of
cases
HR (95% CI)
Model 1 Model 2
PRS score
Tertile 1 1440 13 1.00 (Ref.) 1.00 (Ref.)
Tertile 2 1442 36 2.74 (1.45–5.17) 2.83 (1.50–5.34)
Tertile 3 1483 40 2.94 (1.57–5.49)* 2.98 (1.59–5.58)*
BMI
< 25 kg/m2 2331 40 1.00 (Ref.) 1.00 (Ref.)
25–30 kg/m2 1434 28 1.18 (0.73–1.92) 1.15 (0.71–1.87)
> 30 kg/m2 536 19 2.29 (1.32–3.98) 2.10 (1.20–3.68)
Physical activity per week
0 h 762 21 1.00 (Ref.) 1.00 (Ref.)
0–2 h 1645 36 0.77 (0.45–1.33) 0.77 (0.44–1.32)
> 2 h 1910 30 0.56 (0.32–0.98) 0.59 (0.33–1.03)
Regular smoker (cigarette smoking >1 year)
No 1773 26 1.00 (Ref.) 1.00 (Ref.)
Yes 2546 62 1.65 (1.04–2.61) 1.59 (1.00–2.52)
Alcohol consumption
No 104 2 1.00 (Ref.) 1.00 (Ref.)
Yes 2861 58 1.03 (0.25–4.22) 1.12 (0.27–4.70)
Total no. number of breast cancer patients, No. of cases number of psoriasis
cases, HR hazard ratio, CI confidence interval, BMI body mass index, PRS
polygenic risk score
Analyses were based on a subset of the regional cohort with information on
genetic and lifestyle factors. Significant associations are denoted in boldface.
Genetic predisposition for psoriasis was defined by a PRS including 35 genetic
variants for psoriasis susceptibility. Patients were grouped into tertiles by their
genetic risk. Model 1: adjusted for age and calendar period of breast cancer
diagnosis. Model 2: all of the risk factors were put into the model, including
radiotherapy and mastectomy. Missingness on all variables is <5%, except for
alcohol consumption (32.1%, N = 1400). No evidence of non-proportional
hazards was found
*P for trend < 0.001, tested by log-linear trend test
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reported in a previous study (13%) using skin screening
results [7]. The use of a clinical definition may have re-
sulted in underestimation of the incidence estimates
while capturing the more severe cases.
The increased risk of psoriasis after breast cancer is
clinically plausible, as some treatments for breast cancer
can cause dermatological side effects. In the regional co-
hort, we found an association between radiotherapy and
risk of psoriasis. Skin trauma (a burn, scratch, bruise,
cut, etc.) has been reported as a triggering factor for 43–
76% of incident psoriasis cases [12]. The highest risk of
psoriasis within the first year after diagnosis could also
partly be explained by trauma caused by ionizing radi-
ation. Compared to lumpectomy, we observed a signifi-
cantly higher risk of psoriasis in breast cancer patients
with mastectomy in the multivariable model. Patients
with mastectomy usually experience more wound com-
plications and delayed wound healing [29]. As the two
main pathogenic features of psoriasis (abnormal kera-
tinocyte differentiation and hyperproliferation of kerati-
nocytes) are also secondary to the altered development
of the normal wound healing process [30], prolonged
wound healing could trigger psoriasis onset. Addition-
ally, an increased risk of psoriasis could be explained by
psychological reactions to the disease diagnosis and
treatment decision, since a severe stressful life event has
been identified as a potential trigger for psoriasis [31].
Both factors (treatment and stress reaction to the actual
diagnosis) could potentially explain the observed peak in
psoriasis incidence shortly after diagnosis.
Our study further identified obesity, smoking, and a high
genetic predisposition as independent risk factors of psoria-
sis in patients with breast cancer. Psoriasis is a highly herit-
able disease; the heritability rate is estimated to be 70% [13].
Previous studies have reported substantially higher relative
risks of psoriasis when comparing the highest to the lowest
quartile of the PRS, with risks being inversely correlated to
the age of psoriasis diagnosis [17, 32, 33]. Although these re-
sults are not directly comparable to our findings, lower rela-
tive risks with genetic predisposition are anticipated in our
study population because of the older age at psoriasis onset
(after diagnosis of breast cancer). Smoking and increased
BMI are also established risk factors for psoriasis in the gen-
eral population [34]. The effect of smoking and obesity in
the breast cancer cohort was comparable to effects previ-
ously observed in the general population [14, 16].
The main strength of our study is the large sample size
and the population-based design using Swedish health
registers, which minimizes selection and information
biases. Other strengths include the abundant information
of treatment, lifestyle, and genetic information in the re-
gional breast cancer cohort. We also acknowledge several
limitations. The validity (positive predictive value) of psor-
iasis diagnoses in the Swedish Patient Register is about
81% [19], which indicates a possibility of misclassification
(e.g., misclassified radio dermatitis as psoriasis). Although
mild cases of radio dermatitis and psoriasis have some
symptoms in common (erythema on the skin and some-
times desquamation), severe psoriasis is quite different
from radio dermatitis [35], and in contrast to dermatitis,
does not disappear after a couple of weeks. As the patient
register mostly includes the severe cases of psoriasis, this
misclassification should not have influenced our results.
Furthermore, because of increased medical surveillance,
breast cancer patients may have received a diagnosis that
would, in a healthy person, continue to be undiagnosed.
However, the long-term risk of psoriasis vulgaris (up to
12 years) argues against surveillance bias being a pure ex-
planation for the increased psoriasis risk observed.
Conclusions
The overall risk of psoriasis is slightly increased among
patients with breast cancer compared to the general
population. While the relative risk of psoriasis is highest
within the first year of diagnosis, the risk of psoriasis
vulgaris remained increased up to 12 years. Independent
risk factors of psoriasis in breast cancer patients are
radiotherapy, mastectomy, smoking, obesity, and a high
genetic predisposition. Our findings emphasize the com-
plex etiology of psoriasis in patients with breast cancer.
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